| |
|
|
|
|
|
|
|||
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2819-2827. Prepublished online as a Blood First Edition Paper on June 25, 2007; DOI 10.1182/blood-2007-03-077792.
REVIEW ARTICLE Galectins in the tumor endothelium: opportunities for combined cancer therapy1 Angiogenesis Laboratory, Research Institute for Growth and Development (GROW), Department of Pathology, University Maastricht and Academic Hospital Maastricht, the Netherlands; 2 Institute Jacques Monod, Unité Mixte de Recherche, Centre National de la Recherche Scientifique (UMR CNRS) 7592, Paris, France; 3 Department of Pathology and Laboratory Medicine, University of California School of Medicine, Los Angeles, CA Galectins are emerging as a family of proteins that play an important role in several steps of tumorigenesis. Evidence is accumulating that galectins are expressed by the tumor endothelium, where they contribute to different steps of tumor progression such as immune escape and metastasis. Recent studies have identified an important role for galectins in tumor angiogenesis. Moreover, it has been shown that galectins in the endothelium can be targeted for therapeutic applications. This opens a window of opportunity for the development of tumor-type independent treatment strategies. This review focuses on the expression of galectins in the tumor endothelium, their contribution to tumor progression, and their application in tumor-type independent cancer therapy.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||